ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer
The results from the following study were presented at the [...]
Potential predictive biomarker of response to VEGF treatment in metastatic kidney cancer
A recent study published on PLOS/ONEÂ has identified three genetic mutations/alterations [...]
Second-line treatment with axitinib in favourable risk patients
Results from a phase 2 study to assess the activity [...]
Real world safety and efficacy of nivolumab for kidney cancer
A recent study reports the real-world safety and efficacy of [...]
Immunoscore system to predict kidney cancer patient outcomes
A recent study by researchers in China, and published in [...]
Surgery may not be the most appropriate frontline treatment for metastatic kidney cancer
Results of the phase 3 SURTIME trial comparing pretreatment with [...]
Deferred cytoreductive nephrectomy in kidney cancer fails to improve progression-free survival
Results from the phase 3 CARMENA study, published in the [...]
Advances and next steps in kidney cancer
In an interview with OncLive, Dr Toni Choueiri from Harvard Medical [...]
Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer
A recent phase 2 study evaluated the combination of bevacizumab [...]
Safety and efficacy of nivolumab plus TKI combinations in advanced kidney cancer
A phase 1 study has evaluated the safety and efficacy [...]
